Bariatric surgery outperforms GLP-1 medications in protecting kidney function

A Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery was associated with a significant decrease in the progression of chronic kidney disease compared to those who received GLP-1 diabetes medications. The paper was published in Annals of Surgery.

AbbVie’s $8.7B neuro gambit; Landmark sickle cell approvals; Roche buys a GLP-1 company; Endpoints 100 biotech survey; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit

December 10, 2023

Opinion | ‘The Most Bang for Its Buck’: What We Heard This Week

“This strategy has ‘the most bang for its buck’.” — Sara Karaba, MD, PhD, MHS, of Johns Hopkins University School of Medicine in Baltimore, on

July 8, 2024

Research potentially expands options for patients with aggressive childhood cancer

Research is shedding light and potentially expanding options for patients living with Medulloblastoma, an aggressive childhood cancer.

January 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.